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Malaria is a killer disease caused by infection with species of the 
protozoan parasite, Plasmodium. The most deadly of these parasites 
is Plasmodium falciparum, for which the estimates of morbidity and 
mortality in Africa were 219 million and 435 000, respectively, in 
2017.1 Although several control methods have been employed with 
substantial success, malaria continues to place a heavy burden on 
the health systems and economies of the countries affected. Experts 
agree on the need for the development and subsequent deployment 
of an effective vaccine, which would be the most cost-effective 
means of disease control and could even lead to elimination of ma-
laria. However, despite decades of research in malaria vaccine de-
velopment, a highly effective vaccine remains elusive. RTS,S/AS01, 
the most advanced malaria vaccine so far, has 30% efficacy of short-
lived protection.2
A better understanding of the host immune response to ma-
laria, and particularly how to induce and maintain protective levels 
of circulating antibodies, would be highly valuable for producing 
effective vaccines which provide long-lasting protection from ma-
laria. Through extensive studies of humoral responses to immuniza-
tion with model antigens and in acute viral infections, it is generally 
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B-cell and antibody responses to Plasmodium spp., the parasite that causes malaria, 
are critical for control of parasitemia and associated immunopathology. Antibodies 
also provide protection to reinfection. Long-lasting B-cell memory has been shown to 
occur in response to Plasmodium spp. in experimental model infections, and in human 
malaria. However, there are reports that antibody responses to several malaria an-
tigens in young children living with malaria are not similarly long-lived, suggesting 
a dysfunction in the maintenance of circulating antibodies. Some studies attribute 
this to the expansion of atypical memory B cells (AMB), which express multiple in-
hibitory receptors and activation markers, and are hyporesponsive to B-cell receptor 
(BCR) restimulation in vitro. AMB are also expanded in other chronic infections such 
as tuberculosis, hepatitis B and C, and HIV, as well as in autoimmunity and old age, 
highlighting the importance of understanding their role in immunity. Whether AMB 
are dysfunctional remains controversial, as there are also studies in other infections 
showing that AMB can produce isotype-switched antibodies and in mouse can con-
tribute to protection against infection. In light of these controversies, we review the 
most recent literature on either side of the debate and challenge some of the cur-
rently held views regarding B-cell responses to Plasmodium infections.
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accepted that there are two types of long-lived pathogen-specific 
cells of the B-cell lineage commonly persisting in the memory pool: 
long-lived plasma cells, which secrete specific antibodies, in some 
cases for life; and memory B cells, which confer rapid and enhanced 
responses to secondary pathogen challenge. Follicular helper T-cell 
(Tfh) and germinal center (GC) B-cell responses are essential to gen-
erate isotype-switched long-lived plasma cells and memory B cells3 
(Figure 1A). An understanding of whether and how the immune re-
sponse is compromised, and of the true longevity of the memory 
compartments in Plasmodium infection is necessary for successful 
vaccine development.
Protozoan parasites, such as Plasmodium, have complex life cy-
cles and, in many cases, different cellular forms within the vertebrate 
host. The vast majority of protozoan parasites give rise to long-lasting, 
and in some cases, lifelong, chronic infections, dramatically shaped 
by sophisticated immune evasion mechanisms which include a com-
plex and diverse antigenic repertoire. Thus, protozoan parasites rep-
resent a substantial challenge to the immune system. Mechanisms 
that regulate B-cell responses to Plasmodium species have gained 
increasing attention in recent years. It is now well-established that B 
cells and antibodies are critical to control Plasmodium infection and 
to provide immunity to reinfection.4-10 Plasmodium-specific antibod-
ies, in particular of the IgG subclasses, act by inhibiting Plasmodium 
replication and cell invasion, opsonizing extracellular forms as well as 
infected red blood cells for their destruction by phagocytic cells, and 
promoting lysis by the complement.11-13
In contrast, Plasmodium infections trigger a series of tempo-
rary yet striking events that can potentially alter Plasmodium-spe-
cific B-cell responses. These include pronounced inflammation14 
polyclonal B-cell activation and hypergammaglobulinemia,15-17 al-
terations in splenic and bone marrow microarchitecture,18-20 and 
alteration in hematopoiesis.21,22 Moreover, a series of field studies 
have suggested that B cell responses to Plasmodium spp. might be 
dysfunctional, with poor acquisition of long-lasting B-cell responses 
and accumulation of exhausted B cells.23-25 An intriguing subset 
of B cells expressing the transcription factor T-bet, termed AMB, is 
expanded in subjects exposed to Plasmodium infection.23 B cells with 
similar phenotypical characteristics have been observed in response 
to other infections,23,26-28 autoimmunity,29 and aging.30 Whether 
T-bet+ AMB cells contribute to protection from infection or rather 
represent a dysfunctional B-cell subset that leads to parasite per-
sistence and pathology remains a focus of intense debate.
Here, we will review and challenge some currently held views 
regarding B-cell responses to malaria, with a focus on the longevity 
of the circulating antibody response and potential roles of AMB in 
Plasmodium infection in humans and mice.
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Immunological memory refers to long-lived immunity sustained 
in the absence of pathogen re-exposure. The B-cell response to a 
pathogen presents three distinct phases (Figure 1B): (a) Expansion 
and activation: encounter with the pathogen results in the activation 
and extensive proliferation of B cells, leading to several fold increase 
in the frequency of pathogen-specific B cells as well as the produc-
tion of pathogen-specific antibodies by plasmablasts and short-lived 
plasma cells; (b) Contraction: as the pathogen load is controlled by 
the immune response or curtailed by drug treatment, both the fre-
quency of pathogen-specific B cells and the titer of pathogen-spe-
cific antibodies drop significantly, (c) Memory: following pathogen 
clearance, a subset of pathogen-specific long-lived plasma cells and 
memory B cells survive the contraction phase; the former continue 
to produce pathogen-specific antibodies, sustaining their circulat-
ing levels above background; the later recirculate through blood and 
secondary lymphoid organs readily armed for a second encounter 
with the same pathogen which initiated the response. Subsequent 
encounters with the same pathogen have a cumulative effect, result-
ing in increased precursor frequency of pathogen-specific memory 
B cells with each round of exposure. Due to increased frequencies, 
reduced activation threshold, as well as isotype switching and affin-
ity maturation resulting from GC reactions, the response of memory 
B cells is typically faster and of greater magnitude compared with 
   & !   Ɛ Պ Pathogen-specific B-cell responses. (A) Schematic 
representation of the germinal center (GC) B-cell response, which 
results in the generation of two arms of B-cell memory, long-lived 
plasma cells and memory B cells. (B) Schematic representation 
of the kinetics of B-cell responses to pathogens, showing the 
expansion/activation phase (1), the contraction phase (2), and 
the memory phase (3). FDC: follicular dendritic cell; Tfh: follicular 
helper T cell
ՊՍՊ |ՊƒPÉREZ-MAZLIAH ET AL.
that of naive B cells, and results in faster and greater production of 
antibodies of switched isotypes and increased affinity.31
While phases 1 and 2 can typically last for weeks to months, the 
memory phase can last for years to decades and even for life in the 
absence of pathogen re-exposure.32,33 Long-term immunity is a fea-
ture of many systemic infections such as mumps, polio, yellow fever, 
smallpox, measles, and rubella.32,34 Studies showed that detectable 
antibody titers to smallpox could be sustained for over 75 years after 
a single vaccination,35,36 and smallpox-specific memory B cells could 
be detected in the blood of vaccinees up to 60 years postvaccina-
tion.37 Amanna and colleagues performed a longitudinal analysis of 
antibody titers and memory B-cell frequencies specific for viral an-
tigens (vaccinia, measles, mumps, rubella, varicellazoster virus, and 
EpsteinBarr virus) and nonreplicating antigens (tetanus and diph-
theria).32 Both antibody responses and memory B-cell responses 
were remarkably stable and long-lived, with antibody responses 
half-lives ranging from an estimated 50 years for varicellazoster 
virus to more than 200 years for other viruses such as measles and 
mumps.32 Similar longevity of virus-specific B-cell memory was ob-
served to natural exposure, as demonstrated by the identification of 
memory B cells specific for the 1918 pandemic strain of influenza 
virus circulating in the blood of survivors 90 years after primary ex-
posure.33 In comparison, antibody responses to tetanus and diph-
theria showed a shorter half-life (11-27 years) but still lasting at least 
a decade, and even over 50 years in some diphtheria cases.32,35,38
Plasmodium infection, with its complex life cycle, antigenic vari-
ation/polymorphism, and its ability to establish chronic infection 
could well influence development and longevity of B-cell responses, 
and might not necessarily reflect the kinetics observed after acute 
viral or bacterial infections or vaccination. In fact, immunity to 
Plasmodium parasites is acquired much less efficiently than in most 
viral and bacterial infections, where a single infection is enough 
(sometimes) for life-long protection.39
Plasmodium parasites present two very distinctive stages in 
the mammalian host (Figure 2A). An initial pre-erythrocytic or liver 
stage, during which Plasmodium sporozoites invade hepatocytes. 
The liver stage can last between 2 and 7 days,40 depending on the 
parasite and host species, and does not lead to clinical disease. The 
liver stage is followed by a more prolonged erythrocytic stage in 
which Plasmodium merozoites invade red blood cells, giving rise to 
a continuous cycle of invasion, replication, and cell destruction fol-
lowed by more invasion, leading to clinical manifestations which in 
some cases can be severe or even lethal. As mentioned, Plasmodium-
specific antibodies confer protection from Plasmodium blood-stage 
infection in both human and mice.41 However, in humans, the pres-
ence of Plasmodium-specific antibodies alone seems not sufficient to 
prevent reinfection.
In areas of stable transmission, Plasmodium-associated life-
threatening disease is very much restricted to young children under 
5 years of age and pregnant women.41,42 Immunity to these severe 
clinical manifestations is acquired rapidly, generally after one or two 
infections, and appears to be maintained in the absence of boosting 
by reinfection.43 In contrast, immunity to infection and non-severe 
disease takes several years to develop and requires continuous ex-
posure to the parasite. These observations prompted the hypothesis 
that B-cell responses to Plasmodium parasites might be dysfunc-
tional or suboptimal, and that generation of long-lasting humoral 
memory to the parasite might be defective. In support of this, a se-
ries of field studies showed that titers of Plasmodium-specific anti-
bodies drop rapidly after acute infection.44-47 Moreover, persistent 
infection seems to be required to maintain high titers of Plasmodium-
specific antibodies, as reduction of transmission due to insecticide 
spraying or antimalarial treatment leads to a general reduction of 
Plasmodium-specific antibodies, albeit not to reach background 
levels from naive populations. These field studies have an intrinsic 
limitation in that the source of antibodies cannot be unequivocally 
determined. Circulating antibodies can be produced either by short-
lived activated plasmablasts/plasma cells or from long-lived plasma 
cells as part of a memory response. Thus, a decline in circulating an-
tibodies does not necessarily represent a defect in long-lived plasma 
cells. Measurements of the duration of antibody responses are fur-
ther confounded by likely constant re-exposure to the parasite in 
endemic areas. In order to control for these confounding factors, we 
resorted to study the different compartments of the B-cell response 
   & !   Ƒ Պ Plasmodium infection. (A) Schematic representation 
of pre-erythrocytic (liver) and erythrocytic (blood) stages of 
Plasmodium spp. infection in the mammalian host. (B) Schematic 
representation of the course of erythrocytic P. chabaudi infection in 
C57BL/6 mice
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to Plasmodium using mouse models of infection. We have exploited 
Plasmodium chabaudi infections in mice, which present a series of 
advantages. In particular, similar to human Plasmodium infections, 
P. chabaudi erythrocytic infections in mice give rise to an acute 
phase of infection followed by a distinctive chronic persistent infec-
tion with subpatent parasitemia which can last for up to 3 months, 
thus allowing to study the impact of low-grade chronic infection on 
the B-cell response (Figure 2B). Using this model, we showed that 
long-lived plasma cells that secrete anti-Plasmodium antibodies are 
generated and maintained in the later stages of malaria infections, 
and that these cells are maintained independently of the low-grade 
chronic infection.48 In the same study, using in vitro cultures and 
ELISpot, we showed that a distinctive P. chabaudi-specific memory 
B-cell pool survives for a very prolonged period following complete 
parasite elimination.48 More recently, we confirmed this result using 
ex vivo flow cytometry in combination with natural mosquito trans-
mission.49 Thus, a single Plasmodium infection in mice leads to the 
generation of long-lived plasma cells and memory B cells specific to 
a dominant Plasmodium blood-stage antigen, which are maintained 
above naive background level for very prolonged periods of time 
(presumably for life in mice) independently of the presence of a 
chronic infection.
These results in mice not necessarily contradict with the results 
observed in studies of human malaria. As described in Figure 1B, 
the B-cell response goes through a dramatic expansion phase shortly 
after infection, followed by a contraction phase once clearance of 
the pathogen has begun. Thus, the drop of Plasmodium-specific 
antibodies after the acute infection observed in some field studies 
might not necessarily be evidence of poor B-cell longevity, but rather 
part of a contraction phase characteristic of short-lived effector re-
sponses following reduction in parasite load or exposure to new an-
tigenic variants (Figure 1B). In agreement with this, we have shown 
that Plasmodium-specific antibody titers drop rapidly by several fold 
after P. chabaudi infection in mice, but are then sustained above 
background level for several months.48,50 Moreover, Plasmodium-
specific antibody levels after reinfection display kinetics consistent 
with secondary antibody responses.48,50 Evidence of rapid boosting 
of antibody titers in response to Plasmodium re-exposure has been 
largely documented in areas of seasonal malaria transmission, after 
outbreaks and in travelers.47,51-56 This is strongly indicative of sec-
ondary B cell responses driven by memory B cells. Moreover, al-
though clinical immunity wanes in the absence of exposure, it has 
been documented that individuals, who are no longer exposed, ex-
perience significantly milder forms of the disease and lower levels 
of parasitemia when compared to fully naive individuals.57-59 Thus, 
immunological memory might indeed provide some level of protec-
tion. One possible interpretation of these data is that memory B cells 
contribute to protection from life-threatening symptoms, while clin-
ical immunity to infection might be largely conferred by short-lived 
recently activated antibody-producing cells sustained by persistent 
infection and constant re-exposure. In contrast, the mechanisms 
that control severe disease might be entirely independent of B-cell 
responses and antibodies. Immunity to severe symptoms might be 
related to a change in the type of immune response, such as a re-
duction in inflammatory responses or a switch away from a strong 
Th1 response, as we have shown in mouse models.60 In contrast, 
elimination of infection (mild or asymptomatic malaria) might require 
antibody responses to all variant forms, something we might expect 
to take time to develop.
Constant re-exposure in areas of high transmission is a major 
confounder in estimating the longevity of B-cell responses. Thus, 
evaluating Plasmodium-specific B-cell responses in historically in-
fected individuals, but who are no longer exposed to malaria might 
be the most insightful way to measure longevity. In a study of adult 
Swedish residents who had traveled to malaria endemic areas, 
Plasmodium-specific memory B cells were detected in 80% of these 
individuals. These responses were maintained for prolonged peri-
ods of time, lasting up to 16 years in the absence of re-exposure to 
parasites in some cases. On the other hand, only 30% of travelers 
showed Plasmodium-specific antibodies above naive levels; some 
displayed Plasmodium-specific antibodies after at least a decade in 
the absence of re-exposure.61 In other studies, migrants from en-
demic areas residing in Spain for long periods (>5 years) without 
continuous malaria exposure presented seropositivity of 32%-98% 
for erythrocytic antigens,55 while 88% of migrants residing in France 
showed Plasmodium-specific antibodies, in some cases for up to 
4 years in the absence of re-exposure.62 In studies of malaria out-
breaks in Madagascar followed by drastic reductions in transmission, 
Migot et al showed that most exposed individuals maintained P. fal-
ciparum and P. vivax-specific antibody and memory B cell responses 
above naive levels for as long as 3-8 years.52,53 In a study of subjects 
briefly exposed to a Plasmodium vivax malaria outbreak in Brazil, out-
side of the area in which malaria was endemic, Plasmodium-specific 
antibody titers remained positive in 47% of cases after 7 years.63 
In a study of adults with previous exposure living in an area of ex-
tremely low malaria transmission in Thailand, Wipasa and colleagues 
documented P. falciparum and P. vivax-specific antibody titers and 
memory B cells which persisted for more than 7 years in the absence 
of re-exposure.64 Several other studies have documented stable 
Plasmodium-specific memory B cell56,65-68 and antibody levels69-72 in 
non-re-exposed adults. Moreover, the magnitude and longevity of 
Plasmodium-specific memory B-cell responses was shown to be simi-
lar to the responses to other classic vaccine antigens such as diphthe-
ria and tetanus toxoid,64,65,73,74 suggesting that the immune system 
can indeed mount memory B-cell responses to Plasmodium antigens 
to the same extent as to other antigens. Most of these studies have 
been carried out with adults. However, it seems that previously ex-
posed children who had documented P. falciparum infections several 
years ago, but minimal exposure since, maintain Plasmodium-specific 
memory B cells at similar levels as compared to those of persistently 
exposed children living in a separate but nearby endemic area.75
In contrast, several field studies, including ours, have shown 
that Plasmodium-specific antibody responses can be substantially 
shorter-lived than their cognate memory B-cell responses, particu-
larly in children.46,47,61,75 Moreover, in some cases, Plasmodium-spe-
cific antibody responses were shown to be considerably shorter 
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than tetanus toxoid in the same individuals.46,47,56 This would either 
suggest that while memory B cells can be long-lived, there might be 
specific problems in the maintenance of their cognate plasma cells, 
or that antibodies specific to Plasmodium antigens are mostly gener-
ated by short-lived plasma cells not resident in survival niches such 
as the bone marrow. Similar results have been reported in HIV and 
HBV, where antigen-specific memory B cells were found in circula-
tion in the absence of their corresponding antibodies in contempora-
neous plasma.76 The molecular and cellular basis for this observation 
is unclear. However, there are two schools of thought on the mech-
anisms for long-term maintenance of plasma cells: (a) they could be 
intrinsically long-lived or (b) are prone to decaying over time but 
replenished from the circulating memory B-cell pool. In the latter 
case, it has been argued that this could be mediated by restimula-
tion of memory B cells by either antigen retained in the system, or 
polyclonal stimulants including T cell cytokines and TLR ligands (by-
stander activation).46,77 In addition, environmental factors such as 
nutritional status and co-infections can impact longevity of the hu-
moral response. In this sense, pre-established long-lived plasma cells 
seem to be in constant competition for their survival niches with 
newly recruited plasma cells77 and co-infections with Plasmodium 
parasites and viruses seems to alter humoral responses to both 
viral78 and Plasmodium79 antigens.
Age seems to be another important factor affecting longevity 
of the humoral response, as adults seem to make better long-lived 
antibody responses to Plasmodium antigens than children.44,45,80 
However, it is not clear yet if maturity of the immune system, rounds 
of re-exposure, or a combination of both can explain this phenom-
enon. Finally, low-transmission regions seem to favor the devel-
opment of long-term humoral immunity to malaria.64,65,72,81 Thus, 
Plasmodium-specific memory B cells seem to have a longevity similar 
to that of memory B cells specific to other antigens. On the other 
hand, Plasmodium-specific antibody responses may be shorter lived. 
However, this is not a universal finding,62,64,65,74,82,83 and is proba-
bly influenced by age of the host, nature of the antigen, intensity of 
transmission in specific regions, and natural host-to-host variations. 
Identifying the mechanisms that favor the generation of long-lived 
plasma cells and consequently long-lived antibody responses to 
Plasmodium parasites can critically contribute to the development of 
long-lived protective malaria vaccines, and therefore should receive 
major attention.
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An intriguing subset of B cells expressing the transcription factor 
T-bet, termed AMB, has been shown to be expanded in blood of 
subjects exposed to Plasmodium infection.23 B cells with similar phe-
notypical characteristics have been observed in response to several 
other chronic infections including HCV, HIV, Mycobacterium tubercu-
losis, Toxoplasma gondii, and Leishmania infantum.28,84-86 Moreover, 
their involvement in immune responses seems to go beyond infec-
tions, as B-cell subsets with very similar phenotypes have been 
shown to be expanded with age,30,87 and suggested to be a driving 
force in autoimmune disorders.88 As these B cells have been identi-
fied independently by different research groups working in differ-
ent fields, they have received a variety of alternative denominations, 
including exhausted memory B cells, tissue-like memory B cells, 
age-associated B cells, double negative B cells, and T-bet+ or 
CD11c+T-bet+ B cells. In this review, we will use the denomination 
they were originally given in the field of malaria: AMB. Whether T-
bet+ AMB contribute to protection from malaria infection, or rather 
represent a dysfunctional B-cell subset that leads to parasite persis-
tence and pathology, remains a focus of intense debate.
AMB were first described in the context of malaria by Weiss 
and colleagues over 10 years ago.23 These cells showed a very sim-
ilar phenotype to a FCRL4+ B-cell subset that was described to be 
expanded in the blood of HIV-infected individuals with high viral 
loads.26 More recently, malaria-associated AMB were shown to pref-
erentially express FCRL5 and FCRL3 but not FCRL4 as previously 
thought.24,89 Similar to HIV, high-circulating antigen load (parasite-
mia) seemed to favor the accumulation of this atypical B-cell subset 
in malaria, thus suggesting chronic persistent infection may drive 
the expansion and accumulation of this B-cell subset in peripheral 
blood.23 In the context of HIV, AMB were termed exhausted tis-
sue-like memory B cells, due to their similarity to a memory B-cell 
subset found in human tonsillar tissues.90 In addition to FCRL5 and 
FCRL3, these cells express relatively high levels of other potentially 
inhibitory receptors including, CD22, CD85j, CD85k, LAIR-1, CD72, 
and PD-1, and show a trafficking receptor expression pattern con-
sistent with a profile of migration to inflamed tissues, which includes 
CD11b, CD11c, and CXCR3. AMB are antigen-experienced, class-
switched B cells, which lack the expression of GC markers. Further 
studies demonstrated the expression of the transcription factor T-
bet and the cytokine IFNγ by these cells, also characteristic of Th1 
CD4+ T cells.84,91,92 Although they received the memory denomi-
nation, AMB do not express CD21 or the hallmark human memory 
B-cell marker CD27, and have a substantially shorter life span than 
classical CD27+ memory B cells.26
Comparison of B-cell profiles from children living in a rural com-
munity of P. falciparum transmission with those of age-matched chil-
dren living under similar conditions in a nearby community where P. 
falciparum transmission ceased over 5 years prior to the study shows 
that increases in AMB are driven by P. falciparum exposure, and not 
influenced by other factors commonly associated with malaria, such 
as coinfections and malnutrition.25 Moreover, temporary expansion 
of AMB in blood has been documented in response to human con-
trolled malaria infections.93,94 The appearance of AMB is strongly as-
sociated with high parasitemias or high exposure to the parasite, as 
individuals living in areas of high malaria transmission present higher 
frequencies of AMB than those in areas of moderate transmission.89 
Similarly, repetitive Plasmodium episodes result in higher frequen-
cies of AMB,92 and AMB frequencies are greater in children with 
persistent asymptomatic P. falciparum parasitemia compared with 
parasite-free children.23 Conversely, AMB frequencies decline as 
parasitemias are reduced or eliminated and when there is no further 
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exposure61,74,95,96 supporting the view that the presence of a signif-
icant level of parasitemia over a period of time is necessary for the 
induction and maintenance of AMB cells.
The important question iscan these AMB cells be induced by 
Plasmodium antigens during the infection, and differentiate into an-
tibody-producing cells and respond to malaria antigens the same 
way as classical memory B cells? No studies on human AMB have 
so far directly demonstrated that they differentiate into plasma 
cells, which secrete antibodies. Single-cell antibody cloning from 
circulating AMB obtained from asymptomatic semi-immune adults 
showed that AMB B-cell receptors (BCR) codified for P. falciparum -
neutralizing antibodies, suggesting these cells could potentially con-
tribute to the pool of P. falciparum- neutralizing antibodies detected 
in serum and play a protective role.97 High levels of secretory IgG 
transcripts from cloned AMB that match amino acid sequences of 
antibodies found in circulation support the idea that these cells se-
crete antibodies in vivo.97 However, in vitro restimulation of sorted 
AMB suggests otherwise; there is reduced Ca2+ mobilization, pro-
liferation, cytokine production, and antibody secretion in response 
to BCR cross-linking.24,26 This has led to the hypothesis that AMB 
might represent an exhausted/dysfunctional/anergic B cell subset, 
which might not allow an effective antibody response to the parasite 
to develop and thus promoting chronic infection. However, in vitro 
assays to determine B-cell capacity have relied on culture conditions 
developed for classical memory B cells. FCRL4+CD27-CD21- AMB, 
contrary to classical memory B cells, proliferate poorly in response 
to either BCR ligation or Staphylococcus aureus stimulation, but can 
secrete high levels of immunoglobulins in response to IL-2 and IL-10 
or to IL-2, IL-10, and CD40L.90 Thus, activation requirements for 
AMB might be different from those required by classical memory 
B cells. In addition, the high expression of activation, proliferation, 
and apoptosis markers on AMB24,49,97 might render these cells more 
sensitive to the manipulation required for cell sorting and in vitro 
restimulation.
The majority of the studies of AMB in human malaria have 
been performed on peripheral blood B cells, as the only accessible 
human lymphoid tissue. B cells and other immune cells normally 
initiate their response to antigen in lymphoid organs, whereas 
the blood contains mostly cells either circulating or traffick-
ing to lymphoid organs, and it is not known how far peripheral 
blood represents B-cell responses in lymphoid organs. In addi-
tion, the frequency of B cells in blood specific to any given an-
tigen is very low, which makes difficult the investigation of their 
functional and developmental capacity. Therefore, we used our 
mouse model of mosquito-transmitted P. chabaudi malaria to in-
vestigate Plasmodium-specific memory B cells. Using a transgenic 
mouse strain with high frequencies of B cells specific to the 21-
kDa C-terminal fragment of P. chabaudi merozoite surface protein 
1 (MSP121),
49 Plasmodium-specific AMB could be tracked. We ob-
served the expansion in the spleen of a distinctive P. chabaudi-
specific CD11b+CD11c+ B-cell subset expressing similar surface 
markers as human AMB during the persistent stage of erythro-
cytic infection. In agreement with an AMB phenotype described 
in humans, these cells were class-switched and expressed low lev-
els of CD21 and high levels of mouse FCRL5, CD80, and CD273, 
the last two previously shown to be expressed on mouse memory 
B cells. Transcriptome analysis of these cells compared well with 
previously published data of human AMB transcripts. In agreement 
with data on human AMB, P. chabaudi-specific CD11b+CD11c+ 
B cells expressed high levels of Tbx21 (T-bet), Fcrl5, Ifng, Pdcd1 
(PD1), Mki67, and class-switched immunoglobulins, including Igha, 
Ighg1, Ighg2b, Ighg2c, and Ighg3. Moreover, similar to human AMB, 
P. chabaudi-specific mouse AMB require parasite exposure to 
persist, as their numbers drop to background levels upon reso-
lution of the persistent infection. P. chabaudi-specific AMB also 
displayed high levels of the proapoptotic genes Bad, Bax, Fas, and 
Fasl, low level of the anti-apoptotic gene Bcl2, and a transcriptome 
consistent with active replication and activation.49 In parallel, and 
in agreement with our previous data,48 a P. chabaudi-specific clas-
sical memory B-cell pool expressing different combinations of the 
mouse memory markers CD80, CD273, and CD73 together with 
high levels of Bcl2 developed and persisted long after resolution 
of the infection. Interestingly, mouse FCRL5 was highly expressed 
on all different subsets of P. chabaudi-specific classical memory B 
cells, including IgM+.49 FCRL5 was also highly expressed on classi-
cal memory B cells generated through immunizations of mice.49,98 
Persistent infection therefore seems to drive expansion of P. cha-
baudi-specific mouse AMB, but their existence does not prevent 
the generation of P. chabaudi-specific classical memory B cells nor 
prevent resolution of the infection. These observations support 
the view that constant immune activation rather than impaired 
memory function leads to the accumulation of AMB in malaria. 
Nonetheless, although showing very high levels of IgG transcripts, 
the contribution of P. chabaudi-specific AMB to the serum anti-
body pool and to protection from P. chabaudi infections remains 
to be demonstrated.
The occurrence of CD11b+CD11c+T-bet+ AMB-like B cells 
has been extensively described in mouse models of chronic viral 
and bacterial infections, and in many cases are shown to be a 
fully functional B cell subset able to contribute to protection 
from infection.99-101 The peak of CD11c+T-bet+ B-cell produc-
tion in the spleen is detected early after Ehrlichia muris peak in-
fection, and these cells persist thereafter in lower numbers but 
above background levels accompanying the persistent infection. 
These cells very much resemble the P. chabaudi-specific AMB (ie, 
CD11b+CD11c+Tbet+CD273+CD73+CD80+Fas-Lhi), with the ex-
emption of being IgM+. Moreover, similar to P. chabaudi-specific 
AMB, the CD11c+T-bet+ B cells expanded in response to E. muris 
resembled plasmablasts, including expression of CD138.49,101 In 
accordance, these cells give rise to antibody-secreting cells that 
produced antibodies which recognized E. muris antigens.102,103 
Moreover, AMB-like cells have also been shown to be the orig-
inal source of protective virus-specific antibodies in mice. A 
CD11b+CD11c+T-bet+ AMB subset appears at the peak of murine 
gamma herpesvirus 68 (gHV68), lymphocytic choriomeningitis 
virus (LCMV), murine cytomegalovirus (MCMV), vaccinia, and 
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Friend virus infections.100,104 These cells are required for produc-
tion of virus-specific IgG2a and are critical to clear gHV68 infec-
tion.100,104 A T-bet+ AMB subset is also critical for the production 
of protective IgG2a and to control chronic LCMV cl13 infection.99 
Thus, in the strong Th1-biased context of intracellular bacterial 
and viral infections, AMB appear to be a source of protective 
antibodies.
A subset of CD11c+T-bet+ AMB-like cells, originally termed 
age-associated B cells, have also been shown to expand in sev-
eral mouse models of autoimmune disorders as well as in blood 
of subjects suffering autoimmune diseases such as rheumatoid 
arthritis, systemic lupus erythematosus, multiple sclerosis, and 
Crohn's disease.88,105-109 In mouse models of lupus-like disease, 
AMB-like cells expressed CD138, characteristic of antibody se-
creting plasma cells/plasmablasts, and directly contributed to 
the production of auto-antibodies.110 Moreover, in the context 
of autoimmune disorders, AMB-like cells showed potent anti-
gen-presenting capacity and production of proinflammatory cy-
tokines.108,110,111 Similar to malaria, AMB-like cells identified in 
autoimmunity showed signs of previous activation and prolifer-
ation in vivo, and defective Ca2+ signaling and poor proliferation 
in response to BCR stimulation in vitro.112,113 Surprisingly, pro-
tective AMB-like cells generated during E. muris infection also 
produced polyreactive autoantibodies.102,103 This is intriguing 
and surprising, as these autoantibodies seem not to drive pathol-
ogy in the E. muris infection model. A recent study showed that 
an AMB-like CD11c+T-bet+ B-cell subset expanded in the spleen 
during acute blood stage Plasmodium yoelii 17XNL infection in 
mice and secreted autoantibodies specific to erythrocyte phos-
phatidylserine, which appear to drive anemia.114 This opens the 
intriguing possibility that AMB might contribute to malaria pa-
thology through the production of autoantibodies.
Nonetheless, whether protective or pathogenic, the outstand-
ing majority of data on AMB-like cells obtained in viral and bacterial 
infections as well as autoimmune disorders is so far not compatible 
with the hypothesis that AMB are exhausted or anergic. It might be 
argued that these AMB-like subsets generated in different immune 
scenarios, despite sharing an impressive number of key characteris-
tics, are in fact intrinsically different from the AMB cells observed 
in malaria. Alternatively, although being the same subset, different 
immune scenarios might differentially affect their function, with ma-
laria and HIV preferentially driving AMB to exhaustion unlike other 
Th-1-biased chronic infections such as LCMV. If the latter is the case, 
then those signals affecting AMB which are unique to malaria and 
not shared by other chronic infections or autoimmune disorders re-
main to be identified.
Together, most of these studies in human and experimental 
malaria as well as other infections suggest that AMB represent an 
effector B-cell subset generated in, and sustained by, persistent an-
tigen exposure. However, there are reports of relatively long AMB 
persistence in the apparent absence of malaria exposure,68 and 
long-lived T-bet+ memory B cells have been described in the E. muris 
infection model.115 Therefore, AMB in malaria and beyond represent 
an exciting field of study with many unanswered questions. What is 
the true nature of AMB? Do they contribute to protection, pathol-
ogy, or both? Are they dysfunctional/exhausted/anergic? Do they 
contribute to the memory pool?
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Although there is evidence of T-independent B1 B cells, which 
bridge innate and adaptive responses, producing memory responses 
(B1 cells defined in mice by expression of IgMhiIgDloCD23ƴB220lo, 
and in humans by CD20+CD27+CD43+CD38lo/int), it is the adaptive 
response of B2 B cells (in mice B220+AA4.1ƴCD23+IgMintIgDhi, and 
humans CD20+CD27+CD43ƴ B cells), and GC interactions which are 
critical for long-lasting B-cell responses in the majority of memory 
responses.31,116,117 Despite the importance of antibody responses 
in malaria, details on GC formation and activation/regulation of 
T cell help by follicular helper T-cell in malaria are only starting to 
emerge. CD4+ T cells producing IL-21, a characteristic cytokine of 
Tfh, and Tfh defined by expression of PD-1 and CXCR5 are present 
in peripheral blood mononuclear cells from malaria-exposed im-
mune adults118-120 and in some cases, correlate with P falciparum-
specific IgG antibodies in children with acute P. falciparum malaria.121 
Alterations in the GC B-cell response to Plasmodium infection will 
very likely affect generation of long-lasting B cell memory, but this is 
difficult to investigate fully using human peripheral blood cells, and 
we need to turn to experimental models to elucidate GC interac-
tions in malaria. Plasmodium infections in mice trigger a robust GC 
response, and CD4+ T cells producing IL-21, of which a substantial 
proportion have a Tfh cell phenotype, are required to generate GC 
B-cell and IgG responses, and to resolve P. chabaudi and P. yoelii in-
fections.10,50,122-124 Moreover, mice deficient in IL-21 signaling are 
not immune to reinfection, and fail to generate P. chabaudi-specific 
long-lived plasma cells and memory B cells.10 P. chabaudi-specific 
IgM responses are not altered in the absence of IL-21 signaling, thus 
showing that IgM is not sufficient to clear the infection,10 and that 
IL-21 is essential to generate long-lasting class-switched protective B 
cell responses. Although IL-21 is not required to activate Tfh cells in 
P. chabaudi infections, Tfh cells are an important source of IL-21 and 
are also essential to generate class-switched antibody responses and 
clear the infection.10,122
The pattern recognition receptor cyclic GMP-AMP synthase 
(cGAS), ICOS, and IL-10 signaling on B cells are all required for GC 
B-cell and IgG responses,125 and this is the case also in experimen-
tal P. yoelii infections.123,126,127 Thus, these signals are probably also 
essential for generation of Plasmodium-specific memory B cells. 
The signaling lymphocytic activation molecule (SLAM)-associated 
protein (SAP), shown to be necessary for GC and B-cell memory 
responses to immunizations and viral infections,128,129 has only a 
partial impact on IgG and GC responses in P. chabaudi infections, 
but SAP does contribute to some control of chronic infection.122 
A requirement for SAP interactions in immunity to reinfection in 
Plasmodium remains unexplored.
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Although GC formation clearly takes place in experimental ma-
laria, there is some indication that this may not be optimal as GC 
responses are enhanced by in vivo blockade of CTLA-4, or PD-L1 in 
combination with LAG-3.130,131 However, another interpretation is 
that GC formation during Plasmodium infection is normal, and that 
the blockade is simply overriding the normal mechanism of control 
of GC and B-cell responses. Malaria is characterized by a strong 
Th1like response, which affect B cell responses. The signature Th1 
cytokine, IFN-γ, is responsible for switching to IgG2a/c antibodies 
in mice, and for the human analogues IgG1 and IgG3,132-134 isotypes 
which activate complement and Fcγ receptors on macrophages 
bringing about pathogen killing and phagocytosis. These isotypes 
have been shown to clear viral infections,135,136 and to correlate with 
protection against Plasmodium infections.137,138
There are, however, seemingly opposing views on whether 
Th1 responses promote or impair B cells and GCs in experimen-
tal Plasmodium infections. On -one hand, Plasmodium-specific Th1 
CD4 T cells can support B-cell responses.137-139 On the other hand, 
IFN-γ and TNF-α responses reduce activation of Tfh and GC B-cell 
responses in Plasmodium berghei infections and P. yoelii infections in 
mice.124,126,140,141 Similarly, a Th1-polarized Tfh subset found expanded 
in blood from infected children shows reduced capacity to support B 
cell activation in vitro.119 These data suggest that while Th1 signaling 
is important for switching to potentially protective antibody isotypes, 
in excess it might also negatively limit normal development of the GC 
response. As yet, the direct impact of these signals on the longevity of 
memory B-cell responses has not been demonstrated. However, and 
similar to viral and intracellular bacterial infections, acute P. chabaudi 
blood-stage infection triggers a robust Th1 response,10 and yet we de-
tect substantial GC formation and a long-lived B cell and antibody re-
sponses, suggesting that IFN-γ production by Th1 cells is not sufficient 
per se to prevent robust humoral responses.
Another contribution of Th1 responses and IFN-γ to the B-cell 
response is their role in the generation of AMB cells. Indeed, T-bet 
expression in B cells in malaria is regulated by IFN-γ,92 triggered by 
a combination of CD40, IL-12, and IL-18 signaling. AMB cells are 
not activated by cross-linking the BCR unlike classical memory B 
cells, which may explain why they are difficult to activate in vitro, 
but age-associated CD11c+T-bet+ B cells can be activated by TLR 7 
and 9 signaling,87,110 and antigen-specific AMB-like B cells in mice 
are transiently expanded after immunization with a TLR7/8 ligand 
together with Hen Egg Lysosome100 or a recombinant Plasmodium 
antigen.49 IFN-γ or IL-21 together with TLR signaling drives the 
generation of CD11c+T-bet+ AMB-like cells,142 which is particularly 
relevant in Plasmodium infections where there is a large co-expres-
sion of IFN-γ and IL-21 by CD4+ T cells.10 Similarly, IL-21 is required 
to activate AMB-like cells in response to E. muris infection,143 and 
IL-21 and SAP are required to activate AMB-like cells during au-
toimmunity.144 These data support the view that the signals to 
activate AMB in a variety of situations including malaria where 
there is or has been chronic antigen presence, are partially but not 
entirely shared with those required for the generation of classical 
memory B cells.
We are left with apparently contradictory findings. The same 
signals that seem to impair GC responses during malaria promote 
generation of AMB-like cells. Are AMB cells a GC subset or are they 
generated outside of the GC, and is T cell support required for their 
generation? Most AMB cells have surface IgG, and Immunoglobulin 
variable regions from AMB generated during malaria are heavily 
mutated, suggesting a GC origin.24,97,145 Signals able to drive AMB-
like cell activation, including IL-21 and SAP, seem to also suggest a 
GC origin, and MHCII has been shown to be required to activate 
AMB like cells to E. muris.143,144 T-bet+ AMB-like cells have been 
suggested to be involved in the formation of spontaneous GC in a 
mouse model of lupus.146 Moreover, extrafollicular development of 
T-bet-expressing plasmablasts has been reported in response to E. 
muris infection,102,143 suggesting that AMB-like cells might also arise 
independently of the GC. To date, the origin of AMB during malaria 
remains uncertain. If, as some studies suggest, AMB and classical 
memory B cells share a common developmental origin,24,145 then a 
key element might be the balance between IL-21 and IFN-γ, with ex-
cessive IFN-γ favoring GC disruption and AMB accumulation, while 
IL-21 supporting both AMB and classical memory B cell generation. 
However, it is important to highlight that the robust IFN-γ responses 
during P. chabaudi and other intracellular viral and bacterial patho-
gens do not preclude protective long-lasting B-cell and antibody re-
sponses, nor disrupt the GC response. In addition, the role of IL-21 
and GC in the generation of AMB in response to Plasmodium infec-
tion remains unexplored. Figure 3 summarizes the main signals, ei-
ther known or predicted, to be involved in the generation of classical 
and AMB.
   & !   ƒ Պ Signals known or suggested to support the 
generation of either classical or atypical memory B cells in response 
to Plasmodium spp. infection. SAP: signaling lymphocyte activation 
molecule (SLAM)-associated protein; ICOS: inducible T cell co-
stimulator; cGAS: pattern recognition receptor cyclic GMP-AMP 
synthase; TLR: toll-like receptor
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Many studies show that B-cell and antibody responses to ma-
laria are short-lived and often low level or absent, particularly in 
young children in endemic areas. Given the very varied methods 
of B cell or antibody measurement in a large variety of studies, 
the different transmission intensities of the study sites, and in 
some cases single time-point measurements at unknown times 
after a detectable parasitemia, it is hard to put together a cohe-
sive picture of what is happening. Low levels of antibodies and/
or drops in antibody titer may be due in part to their production 
by short-lived plasma cells in acute infection (Figure 1B), and we 
do not know when in the kinetics of the humoral response anti-
body measurements have been taken. Thus, the drop in antibody 
titer may well represent the contraction phase of a normal B-cell 
response rather than evidence of a deficient B cell memory re-
sponse to Plasmodium. However, some studies clearly show poor 
Plasmodium-specific antibody responses in endemic areas and we 
need to understand the reasons for this. It is difficult to carry out 
a systematic study over time in children or adults in all field set-
tings following a defined infection. Controlled human Plasmodium 
infections (CHMI) of adults in endemic countries, only recently 
made possible, may help us elucidate this important aspect of the 
humoral response in malaria.
There is, conversely, a large body of literature showing 
long-lived B-cell and antibody responses to Plasmodium para-
sites in humans and animal models, which challenge the con-
cept of Plasmodium infection always driving the B-cell response 
to exhaustion of dysfunction. Studies being performed in areas 
of different transmission intensity with consequently different 
reinfection rates might explain some of the apparent discrep-
ancies. AMB, suggested as a reason for dysfunctional B-cell re-
sponses to malaria, may not be the culprit. Whether they could 
be a source of protective antibodies and thus play a role in im-
munity to Plasmodium as has been shown in other infections in 
experimental models, remains to be conclusively demonstrated. 
The restimulation protocols used to demonstrate AMB anergy 
during malaria have not been exhaustive and might not be ade-
quate to stimulate this subset of B cells. Moreover, even if AMB 
detected in the blood of malaria exposed individuals were indeed 
anergic, this would not rule out the possibility these might be ter-
minally differentiated B-cell subsets which have contributed to an 
antibody response in lymphoid organs during their past history. 
Thus, the true nature of AMB in malaria still remains elusive and 
intriguing, and animal models will very likely shed light on their 
origins, developmental history, and function during infection. 
Understanding the mechanisms that govern differential longev-
ity of protective B-cell responses among different individuals or 
to different Plasmodium antigens will greatly expand our capacity 
to improve antibody-based malaria vaccines. In this regard, it is 
important to keep in mind that a single B cell target might not be 
sufficient to confer protection from complex protozoan parasites, 
including Plasmodium. Putative strategies might combine vaccines 
against different targets which provide protection by different 
mechanisms and target different stages of the parasite life cycle, 
while taking into account the occurrence of polymorphisms on the 
selected targets. Moreover, B-cell responses might not be suffi-
cient, and modulation of other immune arms might be required to 
confer full protection from Plasmodium infection while preventing 
pathology.
)	$"
The authors thank Dr Matthew Lewis for his critical reading 
of the manuscript. JL and DPM are supported by the Francis 
Crick Institute (FC 10101), which receives its funding from the 
UK Medical Research Council, Cancer Research UK, and the 
Wellcome Trust, UK. JL is a Wellcome Trust Senior Investigator 
(WT104777/Z/14/Z). DPM has an Independent Research 
Fellowship in Immunology from Hull York Medical School, UK. 
FMN is a Senior Fellow with EDCTP, and is funded from an MRC/
DFID African Research Leadership Award, and the Wellcome 
Trust (107499/Z/15/Z). RA receives a DELTAS Africa Initiative 
[DEL-15-003] fellowship. The DELTAS Africa Initiative is an in-
dependent funding scheme of the African Academy of Sciences 
(AAS)'s Alliance for Accelerating Excellence in Science in Africa 
(AESA), and supported by the New Partnership for Africa's 
Development Planning, and Coordinating Agency (NEPAD 
Agency) with funding from the Wellcome Trust [107769/Z/10/Z], 
and the UK government. The views expressed in this publication 
are those of the authors and not necessarily those of AAS, NEPAD 
Agency, Wellcome Trust or the UK government. All authors de-
clare that they have no conflicts of interest.
!	
Damián Pérez-Mazliah  https://orcid.org/0000-0002-2156-2585 
Jean Langhorne  https://orcid.org/0000-0002-2257-9733 
!!"
 1. World Health Organization. World malaria report 2018. Geneva, 
Switzerland: World Health Organization; 2018.1-210.
 2. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/
AS02A vaccine against Plasmodium falciparum infection and dis-
ease in young African children: Randomised controlled trial. 
Lancet. 2004;364:1411-1420.
 3. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 
2011;29:621-663.
 4. Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The relationship 
between anti-merozoite antibodies and incidence of Plasmodium 
falciparum malaria: A systematic review and meta-analysis. PLoS 
Medicine. 2010;7:e1000218.
 5. Cohen S, McGREGOR IA, Carrington S. Gamma-globulin 
and acquired immunity to human malaria. Nature. 1961;192: 
733-737.
 6. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clin-
ical human response to immunoglobulin administration in falci-
parum malaria. Am J Trop Med Hyg. 1991;45(3):297-308. 
ƐƏՊ|ՊՊՍ PÉREZ-MAZLIAH ET AL.
 7. Osier FHA, Fegan G, Polley SD, et al. Breadth and magnitude of 
antibody responses to multiple Plasmodium falciparum merozoite 
antigens are associated with protection from clinical malaria. Infect 
Immun. 2008;76:2240-2248.
 8. Burns JM, Dunn PD, Russo DM. Protective immunity against 
Plasmodium yoelii malaria induced by immunization with particu-
late blood-stage antigens. Infect Immun. 1997;65:3138-3145.
 9. von der Weid T, Langhorne J, Honarvar N. Gene-targeted mice 
lacking B cells are unable to eliminate a blood stage malaria infec-
tion. J Immunol. 1996;156:2510-2516.
 10. Pérez-Mazliah D, Ng DHL, Freitas do Rosário AP, et al. Disruption 
of IL-21 signaling affects T cell-B cell interactions and abro-
gates protective humoral immunity to malaria. PLoS Pathog. 
2015;11:e1004715.
 11. Hill DL, Schofield L, Wilson DW. IgG opsonization of merozoites: 
Multiple immune mechanisms for malaria vaccine development. 
Int J Parasitol. 2017;47:585-595.
 12. Teo A, Feng G, Brown GV, Beeson JG, Rogerson SJ. Functional 
antibodies and protection against blood-stage malaria. Trends 
Parasitol. 2016;32:887-898.
 13. Chan J-A, Howell KB, Reiling L, et al. Targets of antibodies against 
Plasmodium falciparuminfected erythrocytes in malaria immunity. 
J Clin Invest. 2012;122:3227-3238.
 14. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial dis-
ease: A consequence of inflammatory cytokine release. Malar J. 
2006;5:1-32.
 15. Donati D, Zhang LP, Chen Q, et al. Identification of a poly-
clonal B-Cell activator in Plasmodium falciparum. Infect Immun. 
2004;72:5412-5418.
 16. Rosenberg YJ. Autoimmume and polyclonal B cell responses during 
murine malaria. Nature. 1978;274:170-172.
 17. Abele DC, Tobie JE, Hill GJ, Contacos PG, Evans CB. Alterations 
in serum proteins and 19S antibody production during the 
course of induced malarial infections in man. Am J Trop Med Hyg. 
1965;14:191-197.
 18. Cadman ET, Abdallah AY, Voisine C, et al. Alterations of splenic 
architecture in malaria are induced independently of Toll-like re-
ceptors 2, 4, and 9 or MyD88 and may affect antibody affinity. 
Infect Immun. 2008;76:3924-3931.
 19. Bockstal V, Geurts N, Magez S. Acute disruption of bone marrow 
B Lymphopoiesis and apoptosis of transitional and marginal zone 
B Cells in the spleen following a blood-stage Plasmodium chabaudi 
infection in mice. J Parasitol Res. 2011;2011:1-11.
 20. Urban BC, Hien TT, Day NP, et al. Fatal Plasmodium falciparum ma-
laria causes specific patterns of splenic architectural disorganiza-
tion. Infect Immun. 2005;73:1986-1994.
 21. Belyaev NN, Brown DE, Diaz A-IG, et al. Induction of an IL7-R + 
c-Kit hi myelolymphoid progenitor critically dependent on IFN-γ 
signaling during acute malaria. Nat Immunol. 2010;11:477-485.
 22. Belyaev NN, Biró J, Langhorne J, Potocnik AJ. Extramedullary 
myelopoiesis in Malaria depends on mobilization of myeloid-re-
stricted progenitors by IFN-γ induced chemokines. PLoS Pathog. 
2013;9:e1003406.
 23. Weiss GE, Crompton PD, Li S, et al. Atypical memory B cells are 
greatly expanded in individuals living in a malaria-endemic area. J 
Immunol. 2009;183:2176-2182.
 24. Portugal S, Tipton CM, Sohn H, et al. Malaria-associated atypical 
memory B cells exhibit markedly reduced B cell receptor signaling 
and effector function. Elife. 2015;4:e07218.
 25. Illingworth J, Butler NS, Roetynck S, et al. Chronic exposure to 
Plasmodium falciparum is associated with phenotypic evidence of 
B and T cell exhaustion. J Immunol. 2013;190:1038-1047.
 26. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell 
exhaustion in a dysfunctional memory B cell compartment in HIV-
infected viremic individuals. J Exp Med. 2008;205(8):1797-1805.
 27. Oliviero B, Mantovani S, Ludovisi S, et al. Skewed B cells in chronic 
hepatitis C virus infection maintain their ability to respond to 
virus-induced activation. J Viral Hepat. 2015;22:391-398.
 28. Joosten SA, van Meijgaarden KE, del Nonno F, et al. Patients with 
tuberculosis have a dysfunctional circulating B-cell compartment, 
which normalizes following successful treatment. PLoS Pathog. 
2016;12:e1005687.
 29. Rubtsov AV, Marrack P, Rubtsova K. T-bet expressing B cells  Novel 
target for autoimmune therapies? Cell Immunol. 2017;321:35-39.
 30. Rubtsova K, Rubtsov AV, Cancro MP, Marrack P. Age-associated 
B cells: A T-bet? dependent effector with roles in protective and 
pathogenic immunity. J Immunol. 2015;195:1933-1937.
 31. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 
2015;15:149-159.
 32. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral im-
munity to common viral and vaccine antigens. N Engl J Med. 
2007;357:1903-1915.
 33. Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived 
from the B cells of 1918 influenza pandemic survivors. Nature. 
2008;455:532-536.
 34. Slifka MK, Ahmed R. Limiting dilution analysis of virus-spe-
cific memory B cells by an ELISpot assay. J Immunol Methods. 
1996;199:37-46.
 35. Hammarlund E, Thomas A, Poore EA, et al. Durability of vaccine-
induced immunity against tetanus and diphtheria toxins: A cross-
sectional analysis. Clin Infect Dis. 2016;62:1111-1118.
 36. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral 
immunity after smallpox vaccination. Nat Med. 2003;9:1131-1137.
 37. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. 
Cutting edge: Long-term B cell memory in humans after smallpox 
vaccination. J Immunol. 2003;171:4969-4973.
 38. Maple PAC, Jones CS, Wall EC, et al. Immunity to diphtheria and 
tetanus in England and Wales. Vaccine. 2000;19:167-173.
 39. Ly A, Hansen DS. Development of B cell memory in malaria. Front 
Immunol. 2019;10:111-137.
 40. Cockburn IA, Seder RA. Malaria prevention: from immunological 
concepts to effective vaccines and protective antibodies. Nat 
Immunol. 2018;19:1199-1211.
 41. EL Silveira, V, Dominguez MR, Soares IS. To B or not to B: 
Understanding B Cell responses in the development of malaria in-
fection. Front Immunol. 2018;9:1-9.
 42. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. 
Antibodies to blood stage antigens of Plasmodium falciparum in 
rural Gambians and their relation to protection against infection. 
Trans R Soc Trop Med Hyg. 1989;83:293-303.
 43. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity 
to non-cerebral severe malaria is acquired after one or two infec-
tions. Nat Med. 1999;5:340.
 44. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K. IgG antibody re-
sponses to Plasmodium falciparum merozoite antigens in Kenyan 
children have a short half-life. Malar J. 2007;6:1318-1319.
 45. Akpogheneta OJ, Duah NO, Tetteh KKA, et al. Duration of nat-
urally acquired antibody responses to blood-stage Plasmodium 
falciparum is age dependent and antigen specific. Infect Immun. 
2008;76:1748-1755.
 46. Weiss GE, Traore B, Kayentao K, et al. The Plasmodium fal-
ciparum-specific human memory B cell compartment ex-
pands gradually with repeated malaria infections. PLoS Pathog. 
2010;6:e1000912.
 47. Crompton PD, Kayala MA, Traore B, et al. A prospective analy-
sis of the Ab response to Plasmodium falciparum before and 
after a malaria season by protein microarray. Proc Natl Acad Sci. 
2010;107:6958-6963.
 48. Ndungu FM, Cadman ET, Coulcher J, et al. Functional mem-
ory B cells and long-lived plasma cells are generated after a 
ՊՍՊ |ՊƐƐPÉREZ-MAZLIAH ET AL.
single Plasmodium chabaudi infection in mice. PLoS Pathog. 
2009;5:e1000690.
 49. Pérez-Mazliah D, Gardner PJ, Schweighoffer E, et al. Plasmodium-
specific atypical memory B cells are short-lived activated B cells. 
Elife. 2018;7:e39800.
 50. Achtman AH, Stephens R, Cadman ET, Harrison V, Langhorne J. 
Malaria-specific antibody responses and parasite persistence after 
infection of mice with Plasmodium chabaudi chabaudi. Parasite 
Immunol. 2007;29:435-444.
 51. Chougnet C, Deloron P, Lepers JP, et al. Humoral and cell-medi-
ated immune responses to the Plasmodium falciparum Antigens 
PF155/RESA and CS protein: Seasonal variations in a popula-
tion recently reexposed to endemic malaria. Am J Trop Med Hyg. 
1990;43:234-242.
 52. Migot F, Chougnet C, Raharimalala L, Astagneau P, Lepers JP, 
Deloron P. Human immune responses to the Plasmodium falci-
parum ring-infected erythrocyte surface antigen (Pf155/RESA) 
after a decrease in malaria transmission in Madagascar. Am J Trop 
Med Hyg. 1993;48:432-439.
 53. Migot F, Chougnet C, Henzel D. et al. Anti-malaria antibody-pro-
ducing B cell frequencies in adults after a Plasmodium falciparum 
outbreak in Madagascar. Clin Exp Immunol. 1995;102:529-534.
 54. Waa JAV, Jensen JB, Akood MA, Bayoumi R. Longitudinal study on 
the in vitro immune response to Plasmodium falciparum in Sudan. 
Infect Immun. 1984;45:505-510.
 55. Moncunill G, Mayor A, Jiménez A, et al. High antibody responses 
against Plasmodium falciparum in immigrants after extended peri-
ods of interrupted exposure to malaria. PLoS ONE. 2013;8:1-11.
 56. Yman V, White MT, Asghar M, et al. Antibody responses to mero-
zoite antigens after natural Plasmodium falciparum infection: 
Kinetics and longevity in absence of re-exposure. BMC Med. 
2019;1-14.
 57. Jelinek T, Schulte C, Infectious RBC. Imported falciparum malaria 
in Europe: Sentinel surveillance data from the European network 
on surveillance of imported infectious diseases. Clin Infect Dis. 
2002;2002(34):572-576.
 58. Matteelli A, Colombini P, Gulletta M, Castelli F, Carosi G. 
Epidemiological features and case management practices of im-
ported malaria in northern Italy 19911995. Trop Med Int.Heal. 
1999;4:653-657.
 59. Perri GD, Solbiati M, Vento S,. West African immigrants and new 
patterns of malaria imported to North Eastern Italy. J Travel Med. 
1994;1994(1):147-151.
 60. do Rosário AP, Langhorne, J. T cell-derived IL-10 and its impact 
on the regulation of host responses during malaria. Int J Parasitol. 
2012;42:549-555.
 61. Ndungu FM, Lundblom K, Rono J, Illingworth J, Eriksson S, 
Färnert A. Long-lived Plasmodium falciparum specific memory 
B cells in naturally exposed Swedish travelers. Eur J Immunol. 
2013;43:2919-2929.
 62. Chougnet C, Deloron P, Savel J. Persistence of cellular and hu-
moral response to synthetic peptides from defined Plasmodium 
falciparum antigens. Ann Trop Med Parasitol. 2016;85:357-363.
 63. Braga EM, Fontes CJF, Krettli AU. Persistence of humoral re-
sponse against sporozoite and blood-stage malaria antigens 7 
years after a brief exposure to Plasmodium vivax. J Infect Dis. 1998; 
177:1132-1135.
 64. Wipasa J, Suphavilai C, Okell LC, et al. Long-lived antibody 
and B cell memory responses to the human malaria parasites, 
Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 
2010;6:e1000770.
 65. Nogaro SI, Hafalla JC, Walther B, et al. The breadth, but not the 
magnitude, of circulating memory B cell responses to Plasmodium 
falciparum increases with age/exposure in an area of low transmis-
sion. PLoS ONE. 2011;6(10):e25582.
 66. Triller G, Scally SW, Costa G, et al. Natural parasite exposure 
induces protective human anti-malarial antibodies. Immunity. 
2017;47:1197-1209e10.
 67. Murugan R, Buchauer L, Triller G, et al. Clonal selection drives 
protective memory B cell responses in controlled human malaria 
infection. Sci Immunol. 2018;3:eaap8029.
 68. Changrob S, McHenry AM, Nyunt MH, et al. Persistence of long-
lived memory B cells specific to duffy binding protein in individuals 
exposed to Plasmodium vivax. Sci Rep. 2018;8:1-11.
 69. Taylor RR, Egan A, McGuinness D,et al. Selective recognition of 
malaria antigens by human serum antibodies is not genetically de-
termined but demonstrates some features of clonal imprinting. Int 
Immunol. 1996;8:905-915.
 70. Drakeley CJ, Corran PH, Coleman PG, et al. Estimating me-
dium- and long-term trends in malaria transmission by using 
serological markers of malaria exposure. Proc Natl Acad Sci. 
2005;102:5108-5113.
 71. Udhayakumar V, Kariuki S, Kolczack M, et al. Longitudinal study 
of natural immune responses to the Plasmodium falciparum apical 
membrane antigen (AMA-1) in a holoendemic region of malaria in 
western Kenya: Asembo Bay Cohort Project VIII. Am J Trop Med 
Hyg. 2001;65:100-107.
 72. Longley RJ, Reyes-Sandoval A, Montoya-Díaz E, et al. Acquisition 
and longevity of antibodies to Plasmodium vivax preeryth-
rocytic antigens in Western Thailand. Clin Vaccine Immunol. 
2016;23:117-124.
 73. Dorfman JR, Bejon P, Ndungu FM, et al. B cell memory to 3 
Plasmodium falciparum blood-stage antigens in a malaria-endemic 
area. J Infect Dis. 2005;191:1623-1630.
 74. Ayieko C, Maue AC, Jura WGZO, et al. Changes in B cell popu-
lations and merozoite surface protein-1-specific memory B cell 
responses after prolonged absence of detectable Plasmodium falci-
parum infection. PLoS ONE. 2013;8:e67230-e67312.
 75. Ndungu FM, Olotu A, Mwacharo J, et al. Memory B cells are a 
more reliable archive for historical antimalarial responses than 
plasma antibodies in no-longer exposed children. Proc Natl Acad 
Sci. 2012;109:8247-8252.
 76. Guan Y, Sajadi MM, Kamin-Lewis R, et al. Discordant memory B 
cell and circulating anti-env antibody responses in HIV-1 infection. 
Proc Natl Acad Sci. 2009;106:3952-3957.
 77. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and 
competition: The challenge of becoming a long-lived plasma cell. 
Nat Publ Gr. 2006;6:741-750.
 78. Ng DHL, Skehel JJ, Kassiotis G, Langhorne J. Recovery of an an-
tiviral antibody response following attrition caused by unrelated 
infection. PLoS Pathog. 2014;10:e1003843.
 79. Matar CG, Anthony NR, O'Flaherty BM, et al. Gammaherpesvirus 
co-infection with malaria suppresses anti-parasitic humoral immu-
nity. PLoS Pathog. 2015;11:e1004858.
 80. White MT, Griffin JT, Akpogheneta O, et al. Dynamics of the anti-
body response to Plasmodium falciparum infection in African chil-
dren. J Infect Dis. 2014;210:1115-1122.
 81. Clark EH, Silva CJ, Weiss GE, et al. Plasmodium falciparum malaria 
in the Peruvian Amazon, a region of low transmission, is associated 
with immunologic memory. Infect Immun. 2012;80:1583-1592.
 82. Deloron P, Chougnet C. Is Immunity to malaria really short-lived? 
Parasitol Today. 1992;8:375-378.
 83. Bouchaud O, Cot M, Kony S, et al. Do African immigrants living 
in France have long-term malarial immunity?. Am J Trop Med Hyg. 
2005;72:21-25.
 84. Knox JJ, Buggert M, Kardava L, et al. T-bet+ B cells are induced by 
human viral infections and dominate the HIV gp140 response. JCI 
insight. 2017;2:92943.
 85. Johrens K, Shimizu Y, Anagnostopoulos I, et al. T-bet-positive and 
IRTA1-positive monocytoid B cells differ from marginal zone B 
ƐƑՊ|ՊՊՍ PÉREZ-MAZLIAH ET AL.
cells and epithelial-associated B cells in their antigen profile and 
topographical distribution. Haematologica. 2005;90:1070-1077.
 86. Rodrigues V, Laforge M, Campillo-Gimenez L, et al. Abortive T fol-
licular helper development is associated with a defective humoral 
response in Leishmania infantum-infected macaques. PLoS Pathog. 
2014;10:e1004096-e1004117.
 87. Hao Y, O'Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell 
subset uniquely responsive to innate stimuli accumulates in aged 
mice. Blood. 2011;118:1294-1304.
 88. Rubtsova K, Rubtsov AV, Thurman JM, Mennona JM, Kappler JW, 
Marrack P. B cells expressing the transcription factor T-bet drive 
lupus-like autoimmunity. J Clin Invest. 2017;127:1392-1404.
 89. Sullivan RT, Kim CC, Fontana MF, et al. FCRL5 delineates func-
tionally impaired memory B cells associated with Plasmodium falci-
parum exposure. PLoS Pathog. 2015;11:e1004894.
 90. Ehrhardt GRA. Expression of the immunoregulatory molecule 
FcRH4 defines a distinctive tissue-based population of memory B 
cells. J Exp Med. 2005;202:783-791.
 91. Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. 
Atypical memory B cells in human chronic infectious diseases_ An 
interim report. Cell Immunol. 2017;321:18-25.
 92. Obeng-Adjei N, Portugal S, Holla P, et al. Malaria-induced interfer-
on-γ drives the expansion of Tbethi atypical memory B cells. PLoS 
Pathog. 2017;13:e1006576-e1006630.
 93. Sundling C, Rönnberg C, Yman V, et al. B cell profiling in malaria 
reveals expansion and remodeling of CD11c+ B cell subsets. JCI 
Insight. 2019;4:126492.
 94. Scholzen A, Teirlinck AC, Bijker EM, et al. BAFF and BAFF re-
ceptor levels correlate with B cell subset activation and re-
distribution in controlled human malaria infection. J Immunol. 
2014;192:3719-3729.
 95. Patgaonkar M, Herbert F, Powale K, et al. Vivax infection alters pe-
ripheral B-cell profile and induces persistent serum IgM. Parasite 
Immunol. 2018;40:e12580-e12614.
 96. Nogaro SI, Hafalla JC, Walther B, et al. The Breadth, but not the 
magnitude, of circulating memory B cell responses to Plasmodium 
falciparum increases with age/exposure in an area of low transmis-
sion. PLoS ONE. 2011;6:e25582.
 97. Muellenbeck MF, Ueberheide B, Amulic B, et al. Atypical and clas-
sical memory B cells produce Plasmodium falciparum neutralizing 
antibodies. J Exp Med. 2013;210:389-399.
 98. Kim CC, Baccarella AM, Bayat A, Pepper M, Fontana MF. FCRL5+ 
memory B cells exhibit robust recall responses. Cell Rep. 2019;27: 
1446-1460e4.
 99. Barnett BE, Staupe RP, Odorizzi PM, et al. Cutting edge: B cell-in-
trinsic T-bet expression is required to control chronic viral infec-
tion. J Immunol. 2016;197:1017-1022.
 100. Rubtsova K, Rubtsov AV, van Dyk LF, Kappler JW, Marrack P. T-box 
transcription factor T-bet, a key player in a unique type of B-cell 
activation essential for effective viral clearance. Proc Natl Acad Sci 
U. S. A. 2013;110:E3216-E3224.
 101. Winslow GM, Papillion AM, Kenderes KJ, Levack RC. CD11c+ T-
bet+ memory B cells: Immune maintenance during chronic infec-
tion and inflammation? Cell Immunol. 2017;321:8-17.
 102. Racine R, Chatterjee M, Winslow GM. CD11c expression identifies 
a population of extrafollicular antigen-specific splenic plasmablasts 
responsible for CD4 T-independent antibody responses during in-
tracellular bacterial infection. J Immunol. 2008;181:1375-1385.
 103. Jones DD, DeIulio GA, Winslow GM. Antigen-driven induction of 
polyreactive IgM during intracellular bacterial infection. J Immunol. 
2012;189:1440-1447.
 104. Rubtsova K, Rubtsov AV, Halemano K, et al. T cell production of 
IFNy in response to TLR7/IL-12 stimulates optimal B cell responses 
to viruses. PLoS ONE. 2016;11:1-15.
 105. Wehr C, Eibel H, Masilamani M, et al. A new CD21low B cell pop-
ulation in the peripheral blood of patients with SLE. Clin Immunol. 
2004;113:161-171.
 106. Frisullo G, Nociti V, Iorio R, et al. Increased expression of T-bet in 
circulating B cells from a patient with multiple sclerosis and celiac 
disease. Hum Immunol. 2008;69:837-839.
 107. Wang Z, Wang Z, Wang J, Diao Y, Qian X, Zhu N. T-bet-expressing 
B cells are positively associated with Crohn's disease activity and 
support Th1 inflammation. DNA Cell Biol. 2016;35:628-635.
 108. Claes N, Fraussen J, Vanheusden M, et al. Age-associated B cells 
with proinflammatory characteristics are expanded in a proportion 
of multiple sclerosis patients. J Immunol. 2016;197:4576-4583.
 109. Becker AM, Dao KH, Han BK, et al. SLE peripheral blood B cell, 
T cell and Myeloid cell transcriptomes display unique profiles 
and each subset contributes to the interferon signature. PLoS 
One.8:e67003.
 110. Rubtsov AV, Rubtsova K, Fischer A, et al. Toll-like receptor 7 
(TLR7)-driven accumulation of a novel CD11c+ B-cell popula-
tion is important for the development of autoimmunity. Blood. 
2011;118:1305-1315.
 111. Rubtsov AV, Rubtsova K, Kappler JW, Jacobelli J, Friedman RS, 
Marrack P. CD11c-expressing B cells are located at the T cell/B cell 
border in spleen and are potent APCs. J Immunol. 2015;195:71-79.
 112. Isnardi I, Ng Y-S, Menard L, et al. Complement receptor 2/CD21- 
human naive B cells contain mostly autoreactive unresponsive 
clones. Blood. 2010;115:5026-5036.
 113. Rakhmanov M, Keller B, Gutenberger S, et al. Circulating CD21low 
B cells in common variable immunodeficiency resemble tissue 
homing, innate-like B cells. Proc Natl Acad Sci U. S. A. 2009;16.
 114. Rivera-Correa J, Guthmiller JJ, Vijay R, et al. Plasmodium DNA-
mediated TLR9 activation of T-bet+ B cells contributes to autoim-
mune anaemia during malaria. Nat Commun. 2017;8:1-11.
 115. Kenderes KJ, Levack RC, Papillion AM, Cabrera-Martinez B, 
Dishaw LM, Winslow GM. T-Bet+ IgM memory cells generate 
multi-lineage effector B cells. Cell Rep. 2018;24:824-837e3.
 116. Defrance T, Taillardet M, Genestier L. T cell-independent B cell 
memory. Curr Opin Immunol. 2011;23:330-336.
 117. Good-Jacobson KL, Tarlinton DM. Multiple routes to B-cell mem-
ory. Int Immunol. 2012;24:403-408.
 118. Mewono L, Agnandji ST, Matondo Maya DW, et al. Malaria anti-
gen-mediated enhancement of interleukin-21 responses of pe-
ripheral blood mononuclear cells in African adults. Exp Parasitol. 
2009;122:37-40.
 119. Obeng-Adjei N, Portugal S, Tran T, et al. Circulating Th1-cell-type 
Tfh cells that exhibit impaired B cell help are preferentially acti-
vated during acute malaria in children. Cell Rep. 2015;13:425-439.
 120. Roetynck S, Olotu A, Simam J, et al. Phenotypic and functional 
profiling of CD4 T cell compartment in distinct populations of 
healthy adults with different antigenic exposure. PLoS ONE. 
2013;8:e55195.
 121. Mewono L, Matondo Maya DW, Matsiegui P-B, et al. Interleukin-21 
is associated with IgG1 and IgG3 antibodies to erythrocyte-bind-
ing antigen-175 peptide 4 of Plasmodium falciparum in Gabonese 
children with acute falciparum malaria. Eur Cytokine Netw. 
2008;19:30-36.
 122. Pérez-Mazliah D, Nguyen MP, Hosking C, et al. Follicular helper 
T cells are essential for the elimination of Plasmodium infection. 
EBioMedicine. 2017;24:216-230.
 123. Wikenheiser DJ, Ghosh D, Kennedy B, Stumhofer JS. The costim-
ulatory molecule ICOS regulates host Th1 and follicular Th cell 
differentiation in response to Plasmodium chabaudi chabaudi AS 
infection. J Immunol. 2016;196:778-791.
 124. Zander R, Obeng-Adjei N, Guthmiller J, et al. PD-1 co-inhibi-
tory and OX40 co-stimulatory crosstalk regulates helper T cell 
ՊՍՊ |ՊƐƒPÉREZ-MAZLIAH ET AL.
differentiation and anti-plasmodium humoral immunity. Cell Host 
Microbe. 2015;17:628-641.
 125. Laidlaw BJ, Lu Y, Amezquita RA, et al. Interleukin-10 from CD4+ 
follicular regulatory T cells promotes the germinal center response. 
Sci Immunol. 2017;2:eaan4767.
 126. Guthmiller JJ, Graham AC, Zander RA, Pope RL, Butler NS. Cutting 
edge: IL-10 is essential for the generation of germinal center B cell 
responses and anti- plasmodium humoral immunity. J Immunol. 
2017;198:617-622.
 127. Hahn WO, Butler NS, Lindner SE, et al. cGAS-mediated control of 
blood-stage malaria promotes Plasmodium-specific germinal cen-
ter responses. JCI insight. 2018;3:1-18.
 128. Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. SAP 
is required for generating long-term humoral immunity. Nature. 
2003;421:282-287.
 129. Qi H. From SAP-less T cells to helpless B cells and back: dynamic 
T-B cell interactions underlie germinal center development and 
function. Immunol Rev. 2012;247:24-35.
 130. Butler NS, Moebius J, Pewe LL, et al. Therapeutic blockade of PD-
L1 and LAG-3 rapidly clears established blood-stage Plasmodium 
infection. Nat Immunol. 2011;13:188-195.
 131. Kurup SP, Obeng-Adjei N, Anthony SM, et al. Regulatory T cells 
impede acute and long-term immunity to blood-stage malaria 
through CTLA-4. Nat Med. 2017;23:1220-1225.
 132. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A 
novel transcription factor, T-bet, directs Th1 lineage commitment. 
Cell. 2000;100:655-669.
 133. Knox JJ, Kaplan DE, Betts MR. T-bet-expressing B cells during HIV 
and HCV infections. Cell Immunol. 2017;321:26-34.
 134. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switch-
ing and pathogenic autoantibody production. Proc Natl Acad Sci U. 
S. A. 2002;99:5545-5550.
 135. Coutelier JP, van der Logt JT, Heessen FW, Warnier G, Snick JV. 
IgG2a restriction of murine antibodies elicited by viral infections. J 
Exp Med. 1987;165:64-69.
 136. Markine-Goriaynoff D, Coutelier J-P. Increased efficacy of the immu-
noglobulin G2a Subclass in antibody-mediated protection against lac-
tate dehydrogenase-elevating virus-induced polioencephalomyelitis 
revealed with switch mutants. J Virol. 2002;76:432-435.
 137. Dobaño C, Santano R, Vidal M, et al. Differential patterns of 
IgG subclass responses to Plasmodium falciparum antigens in 
relation to malaria protection and RTS. S Vaccination Front Immunol. 
2019;10:13.
 138. Roussilhon C, Oeuvray C, Müller-Graf C, et al. Long-term clinical 
protection from Falciparum Malaria is strongly associated with 
IgG3 antibodies to merozoite surface protein 3. PLoS Medicine. 
2007;4:e320.
 139. Zander RA, Vijay R, Pack AD, et al. Th1-like Plasmodium-spe-
cific memory CD4+ T cells support humoral immunity. Cell Rep. 
2017;21:1839-1852.
 140. Ioannidis LJ, Nie CQ, Ly A, Ryg-Cornejo V, Chiu CY, Hansen DS. 
Monocyte- and neutrophil-derived CXCL10 impairs efficient con-
trol of blood-stage malaria infection and promotes severe disease. 
J Immunol. 2016;196:1227-1238.
 141. Ryg-Cornejo V, Ioannidis L, Ly A, et al. Severe malaria infections 
impair germinal center responses by inhibiting T follicular helper 
cell differentiation. Cell Rep. 2016;14:68-81.
 142. Naradikian MS, Myles A, Beiting DP, et al. Cutting Edge: IL-4, IL-21, 
and IFN-γ Interact To Govern T-bet and CD11c Expression in TLR-
Activated B Cells. J. Immunol. 2016;197:1023-1028.
 143. Yates JL, Racine R, McBride KM, Winslow GM. T cell-depen-
dent IgM memory B cells generated during bacterial infection 
are required for IgG responses to antigen challenge. J Immunol. 
2013;191:1240-1249.
 144. Manni M, Gupta S, Ricker E, et al. Regulation of age-associ-
ated B cells by IRF5 in systemic autoimmunity. Nat Immunol. 
2018;19:407-419.
 145. Zinöcker S, Schindler CE, Skinner J, et al. The V gene repertoires of 
classical and atypical memory B cells in malaria-susceptible West 
African children. J Immunol. 2015;194:929-939.
 146. Domeier PP, Chodisetti SB, Soni C, et al. IFN-γ receptor and 
STAT1 signaling in B cells are central to spontaneous germi-
nal center formation and autoimmunity. J Exp Med. 2016;213: 
715-732.
How to cite this article: Pérez-Mazliah D, Ndungu FM, Aye R, 
Langhorne J. B-cell memory in malaria: Myths and realities. 
Immunol Rev. 2019;00:113. https ://doi.org/10.1111/
imr.12822 
